Biosyngen featured in the “Top 50 Most Innovative Companies of Chinese Biomedicine in 2022”, Pharma Bigstar
On November 10th to 11th, 2022, the Shanghai (Minhang) Biopharmaceutical Industry Innovation Summit and the Universal Cell Therapy Development Forum 2022 were successfully held in Shanghai. The "Top 50 Most Innovative Biopharmaceutical Companies in China 2022" was unveiled during the forum.
(Dr.Han Deping， CEO&CMO of Biosyngen, at the Pharma Star award ceremony)
Focusing on development and production of immunotherapy, Biosyngen is a fast-growing, innovative biotech capable of translating research, developing treatment from bench to bedside. We strive to design cutting-edge immune cell therapies to fulfill unmet clinical needs, thus benefiting cancer patients. With multiple best-in-class and first-in-class pipeline in development, Biosyngen, a Singapore company with a China HQ in Guangzhou, made it into the list of “Top 50 Most Innovative Companies of Chinese Biomedicine in 2022”.
The “Pharma Star”list was initiated by eMedClub research institute. Candidates were nominated and reviewed by a panel of renowned industry experts. Key considerations are given to innovation and R&D capabilities to highlight promising biopharmaceutical companies out of the thousands in the industry.
This honor is a proof of wide recognition Biosyngen receives from industry experts. It highlights the Company’s capabilities in innovation and technical strength. Biosyngen is inspired and motivated to pursue more effective cancer cure and promote the accessibility of treatments for patients worldwide.